FDA warns of serious blood disorder resulting from abuse of Opana ER
October 19, 2012
FDA has warned patients of thrombotic thrombocytopenic purpura (TTP), a serious blood disorder, resulting from misuse of oxymorphone hydrochloride extended-release tablet (Opana ER, Endo).
